We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+3.6%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$955M
AUM Growth
+$74.9M
Cap. Flow
+$18.7M
Cap. Flow %
1.96%
Top 10 Hldgs %
28.16%
Holding
94
New
8
Increased
32
Reduced
32
Closed
4

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$11.3M
2
BDX icon
Becton Dickinson
BDX
+$9.95M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.64M
4
TMO icon
Thermo Fisher Scientific
TMO
+$8.62M
5
MDT icon
Medtronic
MDT
+$8.09M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$13.6M
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$13M
3
CI icon
Cigna
CI
+$10.1M
4
PFE icon
Pfizer
PFE
+$9.23M
5
ELV icon
Elevance Health
ELV
+$8.13M

Sector Composition

Rank Sector Weight
1 Healthcare 98.85%
2 Industrials 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THC icon
26
Tenet Healthcare
THC
$20.9B
$15.3M 1.6%
344,000
+83,000
+32% +$4.93M
BNTX icon
27
BioNTech
BNTX
$23.3B
$13.6M 1.43%
99,000
+9,000
+10% +$1.38M
APLS
28
DELISTED
Apellis Pharmaceuticals
APLS
$13.3M 1.39%
220,000
+10,000
+5% +$592K
MRTX
29
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$13.3M 1.39%
197,067
+7,067
+4% +$523K
COO icon
30
Cooper Companies
COO
$14.9B
$12.8M 1.34%
187,608
+39,608
+27% +$3.03M
HRMY icon
31
Harmony Biosciences
HRMY
$2.27B
$12.3M 1.29%
237,000
-23,000
-9% -$1.12M
ISRG icon
32
Intuitive Surgical
ISRG
$139B
$12.3M 1.29%
50,000
-20,000
-29% -$4.3M
INSP icon
33
Inspire Medical Systems
INSP
$1.73B
$12.3M 1.29%
63,000
+13,000
+26% +$2.61M
ABT icon
34
Abbott
ABT
$188B
$11.6M 1.21%
117,000
-53,000
-31% -$5.65M
NBIX icon
35
Neurocrine Biosciences
NBIX
$16.8B
$9.55M 1%
83,000
-12,000
-13% -$1.22M
HCA icon
36
HCA Healthcare
HCA
$89.6B
$9.35M 0.98%
43,000
+18,000
+72% +$3.59M
BIIB icon
37
Biogen
BIIB
$30.6B
$9.29M 0.97%
+32,782
New +$6.96M
PRVA icon
38
Privia Health
PRVA
$2.86B
$9.27M 0.97%
277,000
-23,000
-8% -$851K
CYTK icon
39
Cytokinetics
CYTK
$10.5B
$9.17M 0.96%
210,000
-20,000
-9% -$963K
RPRX icon
40
Royalty Pharma
RPRX
$25.8B
$9.1M 0.95%
215,000
+65,000
+43% +$2.78M
EW icon
41
Edwards Lifesciences
EW
$53B
$9.05M 0.95%
125,000
+80,000
+178% +$7.7M
ISEE
42
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.73M 0.91%
365,000
+115,000
+46% +$1.51M
RVNC
43
DELISTED
Revance Therapeutics, Inc.
RVNC
$8.66M 0.91%
388,000
-62,000
-14% -$1.26M
IMCR icon
44
Immunocore
IMCR
$1.73B
$8.57M 0.9%
150,000
+10,000
+7% +$477K
DVAX
45
DELISTED
Dynavax Technologies
DVAX
$8.4M 0.88%
733,519
-66,481
-8% -$866K
XNCR icon
46
Xencor
XNCR
$1.6B
$8.23M 0.86%
294,076
-5,924
-2% -$170K
HZNP
47
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$8.1M 0.85%
130,000
-195,299
-60% -$13.6M
PODD icon
48
Insulet
PODD
$9.91B
$7.5M 0.79%
+29,000
New +$7.26M
ESPR
49
DELISTED
Esperion Therapeutics
ESPR
$7.32M 0.77%
900,000
– –
SILK
50
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$6.83M 0.72%
155,000
-20,000
-11% -$860K
1
2
3 4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2022 Portfolio in Review

As of Q3 2022, Rhenman & Partners Asset Management held 94 positions worth $955M, up 8.5% from $880M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rhenman & Partners Asset Management's Q3 2022 filing shows 8 new, 32 increased, 32 reduced and 4 closed positions. Its largest new stake was Insulet: 29,000 shares worth $7.5M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Industrials.

  • Rhenman & Partners Asset Management's largest Q3 2022 buy was Insulet: 29,000 shares worth $7.5M.
  • Rhenman & Partners Asset Management added most to Regeneron Pharmaceuticals in Q3 2022, an estimated $11.3M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $13.6M.
  • Rhenman & Partners Asset Management fully exited Align Technology in Q3 2022, selling an estimated $4.26M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 28% of its $955M portfolio in Q3 2022.
  • Rhenman & Partners Asset Management opened 8 new positions and closed 4 in Q3 2022.
  • Rhenman & Partners Asset Management's portfolio value rose 8.5% quarter-over-quarter to $955M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.